In contrast to BEV, SUT has the big advantage to inhibit several tyrosine-kinase activities that are overexpressed in cancer, which might explain its better efficacy than other combined therapies.46 Further evaluation of sVE-cadherin levels in mRCC patients treated with other TKI is now needed in a prospective study. The gene discussed is CDH17; the disease is cancer.